The first Pd-catalyzed asymmetric allenylic [4+ +1] cycloaddition was successfully developed. Alternatively,tuning the Pd catalyst switched the reactivity toward an unprecedented [4+ +3] cycloaddition/cross-coupling. Ligands play av ital role in controlling the reaction pathway,a llowing highly selective access to different products from identical substrates.B iological evaluation of the obtained compounds led to the discovery of new antitumor targets.Apossible mechanism is proposed, suggesting two interesting catalytic cycles for the cycloaddition with palladium-butadienyls.T his study also demonstrated the potential and utility of allenic esters as 1,4-biselectrophiles and C 4 synthons for participating in cycloaddition reactions.